2024 ACCP STEP & ESP Webinar: Clinical Pharmacology Considerations for ADCs & Bispecific Antibodies

Live webinar: October 2, 2024 from 12:00 - 1:00 PM ET 

On-demand webinar recording: October 2, 2024 to October 2, 2027

Target audience:

Interprofessional team of MDs, PhDs, PharmDs including Students, Trainees and all levels of professionals seeking an introduction the biological principles and clinical pharmacology considerations for antibody-drug conjugates and bispecific antibodies.

Learning Objectives

After completing this activity, the learner will be able to:

1. Understand the mechanism of actions of ADCs and bispecific antibodies;
2. Apply clinical pharmacology principles in different stages of the development of novel therapeutics;
3. Leverage model-informed drug development approaches in the dose optimization of novel therapeutics;
4. Identify the opportunities and challenges for dose optimization trials.

Description:

Attendees of all experience levels will receive a practical introduction to the exciting modalities of antibody-drug conjugates (ADCs) and bispecific antibodies. ADCs and bispecifics represent new frontiers in immunotherapy and are generating massive interest from prescribers and pharmaceutical companies alike. This webinar, presented by two experts in the spaces of ADCs and bispecifics, will provide a conceptual foundation of the two modalities and how they differ from traditional antibody therapeutics. In the meantime,  ADCs and bispecifics also bring novel challenges in drug development. The clinical pharmacology considerations for evaluating the two modalities, including model-informed approaches and dose optimization, will be discussed and illustrated with case studies.